Biography for John Carroll
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. Carroll is based in Vermont and Texas and can be reached at firstname.lastname@example.org. Follow @JohnCFierce on Twitter.
Articles by John Carroll
With rates of oral cancer linked to HPV infection on the rise, a group of investigators has pinned down a new biomarker that can be used to identify high-risk patients.
An investigative team of heart experts has tracked down a pair of biomarkers they say can flag people who are at risk of having "silent strokes," asymptomatic events that can quietly damage the brain and leave them threatened by even worse incidents of heart and vascular disease.
The preclinical CRO Cenix BioScience has struck a deal to work with Germany's Debiopharm, putting its experts to work finding predictive biomarkers that can be used to advance the biotech's cancer drug candidates.
A group of investigators say they put one theory related to prostate cancer to the test, and came up with some data indicating it's a dead end for developers as well as doctors looking for the right therapeutic strategy for patients.
A team of investigators believe they've come up with a convincing profile for a particular type of tumor cell that could be used as a biomarker for diseases progression as well as a target for drug developers looking to identify a next-gen therapeutic.
Scanning the field of biomarker research for cardiovascular disease, a group of investigators has found some compelling data that suggest the effect of the biomarkers is regularly exaggerated, with signs of bias in the reports. And that clearly could be hurting the medical field's understanding of the biomarkers' significance.
Luminex will put its technology to work on a test that can flag two key biomarkers for Alzheimer's--Aβ42 and t-tau--in cerebrospinal fluid.
A group of investigators at the prestigious Dana-Farber/Children's Hospital Cancer Center in Boston believe they may have identified the Achilles heel for a common malignant tumor found in pediatric oncology.
MDxHealth ($MDXH) is celebrating positive results from recent studies of its prostate cancer molecular diagnostic test.
Investigators from the Mayo Clinic say a recent study helped uncover two new biomarkers for acute kidney injury which should flag at-risk patients significantly earlier than currently used biomarkers.